# Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2018

- Company: [Amphastar Pharmaceuticals, Inc.](/companies/amph.md) (CIK 1297184)
- Form: 10-Q
- Filed: 2018-05-10
- Accepted by EDGAR: May 9, 2018, 19:13 ET
- Period: 2018-03-31
- Accession: 0001297184-18-000029
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1297184/000129718418000029/amph-20180331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1297184/000129718418000029/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2018-01-01 to 2018-03-31 | $41.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-01-01 to 2018-03-31 | $17.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-01-01 to 2018-03-31 | $14.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | −$9.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-01-01 to 2018-03-31 | $18.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-01-01 to 2018-03-31 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | −$7.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-01-01 to 2018-03-31 | 46,514,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2018-01-01 to 2018-03-31 | $8.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2018-01-01 to 2018-03-31 | $12.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2018-01-01 to 2018-03-31 | $7.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-03-31 | $54.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-31 | $174.0m | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $449.8m | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $72.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-31 | $122.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-03-31 | $327.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 21,346 characters.

*The following is a discussion and analysis of the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the “Condensed Consolidated Financial Statements” and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2017, particularly in Item 1A. “Risk Factors”.*

### Overview

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation and intranasal products as well as insulin API products. We currently manufacture and sell over 20 products. We are currently developing a portfolio of 15 generic abbreviated new drug applications, or ANDAs, three generic biosimilar product candidates and six proprietary product candidates, which are in various stages of development and target a variety of indications. With respect to these product candidates, we have three ANDAs, and two NDAs on file with the FDA.

Our largest products by net revenues currently include naloxone hydrochloride injection, lidocaine jelly and sterile solution, phytonadione, and enoxaparin sodium injection. During the first quarter of 2018, we launched medroxyprogesterone acetate and in the fourth quarter of 2017, we launched neostigmine methysulfate.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our core injectable and inhalation product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities including the ability to manufacture raw materials, APIs and other components for our products.

Included in these acquisitions are marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities, from UCB Pharma GmbH. We are in the process of transferring the manufacturing of these products to our facilities in California, which will require approvals from the UK Medicines and Healthcare products Regulatory Agency before we can relaunch the product candidates.

### Business Segments

Our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) API products. The finished pharmaceutical products segment currently manufactures, markets and distributes enoxaparin, naloxone, phytonadione, lidocaine, as well as various other critical and non-critical care drugs. The API segment currently manufactures and distributes RHI API and porcine insulin API. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.

For more information regarding our segments, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Segment Reporting.”

### Results of Operations

### Three Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017

### Net revenues

*(in thousands)*

| Net revenues | Three Months Ended March 31, 2018 | 2017 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Finished pharmaceutical products | $53,117 | $55,934 | $(2,817) | (5)% |
| API | 5,276 | 736 | 4,540 | 617% |
| Total net revenues | $58,393 | $56,670 | $1,723 | 3% |
| Cost of revenues |  |  |  |  |
| Finished pharmaceutical products | $33,392 | $31,624 | $1,768 | 6% |
| API | 7,940 | 2,218 | 5,722 | 258% |
| Total cost of revenues | $41,332 | $33,842 | $7,490 | 22% |
| Gross profit | $17,061 | $22,828 | $(5,767) | (25)% |
| as % of net revenues | 29% | 40% |  |  |

The decrease in net revenues of the finished pharmaceutical products for the three months ended March 31, 2018, was primarily due to the following changes:

*(in thousands)*

| Finished pharmaceutical products net revenues | Three Months Ended March 31, 2018 | 2017 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Lidocaine | $9,782 | $8,289 | $1,493 | 18% |
| Phytonadione | 9,181 | 7,886 | 1,295 | 16% |
| Naloxone | 8,927 | 10,939 | (2,012) | (18)% |
| Enoxaparin | 7,007 | 10,410 | (3,403) | (33)% |
| Epinephrine | 3,223 | 9,574 | (6,351) | (66)% |
| Medroxyprogesterone | 2,706 | — | 2,706 | N/A |
| Other finished pharmaceutical products | 12,291 | 8,836 | 3,455 | 39% |
| Total finished pharmaceutical products net revenues | $53,117 | $55,934 | $(2,817) | (5)% |

In January 2018, we launched Medroxyprogesterone Acetate in a vial form, and in February 2018, we launched Medroxyprogesterone Acetate in a pre-filled syringe form. These were both approved by the FDA in November 2017.

The decrease in sales of enoxaparin was driven by lower unit volumes, which resulted in a decrease of approximately $2.0 million, as well as lower average selling prices, which resulted in a decrease of approximately $1.4 million. We expect that the average selling price and unit volumes of enoxaparin will continue to fluctuate in the near term as a result of competition.

The decrease in sales of naloxone was primarily driven by lower unit volumes. We anticipate that sales of this product may fluctuate due to increased competition driven by future competitor launches.

Higher unit volumes of lidocaine led to an increase in sales of approximately $0.9 million, while higher average selling price caused an increase in sales of approximately $0.6 million. The increase in sales of phytonadione was primarily driven by higher average selling price. Sales of epinephrine decreased primarily as a result of the discontinuation of our epinephrine injection, USP vial product in the second quarter of 2017 in accordance with the FDA’s request. Our epinephrine injection, USP vial product, was marketed under the “grandfather” exception to the FDA’s “Prescription

Drug Wrap-Up” program. In fiscal 2017, we recognized $17.8 million in net revenues for the sale of the discontinued vial product. The remainder of our epinephrine sales was from the pre-filled syringe, which remains on the market.

Sales of RHI API increased primarily due to the timing of customer purchases. We anticipate that sales of insulin API will continue to fluctuate and will likely decrease due to the inherent uncertainties related to sales to MannKind. In addition, most of our API sales are denominated in Euros, and the fluctuation in the value of the Euro versus the dollar has had, and will continue to have, an impact on API sales revenues in the near term.

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. We had a backlog of approximately $1.5 million as of March 31, 2018, primarily related to the timing of customer orders and fulfillment. Our backlog is generally not a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

### Cost of revenues

Changes in cost of revenues and the resulting gross margins decline were primarily due to increased production expenses, lower sales of naloxone, and the discontinuation of our epinephrine injection, USP vial product in the second quarter of 2017. Production expenses increased due to lower productivity at the U.S. facilities as we are in the process of increasing production of newly launched products and increased labor costs resulting from the implementation of new quality standards and increased hourly rates. This trend was partially offset by the sales of medroxyprogesterone acetate which was launched in January 2018. For the three months ended March 31, 2018, a charge of $1.9 million was recorded to adjust certain inventory items and related purchase commitments to their net realizable value, including $1.2 million for enoxaparin items.

The cost of heparin, which is the starting material for enoxaparin, has increased and is expected to increase further, putting downward pressure on our gross margins. However, we believe that this trend will be offset by sales of our higher-margin products, such as medroxyprogesterone acetate and neostigmine that were recently launched, and sodium nitroprusside which we plan to launch.

### Selling, distribution and marketing, and general and administrative

*(in thousands)*

|  | Three Months Ended 2018 | 2017 | Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling, distribution, and marketing | $1,721 | $1,479 | $242 | 16% |
| General and administrative | $10,998 | $11,338 | $(340) | (3)% |

The increase in selling, distribution and marketing expenses is due to increased freight costs and increased expenses at the ANP business. The decrease in general and administrative expense was primarily due to lower legal expenses compared to the same period in 2017 (see Note 17 to the condensed consolidated financial statements for more information regarding litigation matters).

We expect that general and administrative expenses will increase on an annual basis due to increased costs associated with ongoing compliance with public company reporting obligations.

### Research and development

*(in thousands)*

|  | Three Months Ended March 31, 2018 | 2017 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries and personnel-related expenses | $4,085 | $3,980 | $105 | 3% |
| Pre-launch inventory | 738 | 711 | 27 | 4% |
| Clinical trials | 808 | 835 | (27) | (3)% |
| FDA fees | 1,226 | 15 | 1,211 | 8,073% |
| Testing, operating and lab supplies | 4,771 | 3,756 | 1,015 | 27% |
| Depreciation | 1,220 | 1,074 | 146 | 14% |
| Other expenses | 1,412 | 879 | 533 | 61% |
| Total research and development expenses | $14,260 | $11,250 | $3,010 | 27% |

Research and development costs consist primarily of costs associated with the research and development of our product candidates, such as salaries and other personnel related expenses for employees involved with research and development activities, manufacturing pre-launch inventory, clinical trials, FDA fees, testing, operating and lab supplies, depreciation and other related expenses. We expense research and development costs as incurred.

Testing, operating and lab supplies increased due to expenditures on materials for our pipeline products, particularly production of APIs for our pipeline at our ANP facility. FDA fees increased due to the NDA filing fee for a product we currently market under the grandfather exception.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. These costs will fluctuate significantly from quarter to quarter based on the timing of various clinical trials, the pre-launch costs associated with new products, and FDA filing fees. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.

### Gain on sale of intangible assets

*(in thousands)*

|  | Three Months Ended March 31, 2018 | 2017 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Gain on sale of intangible assets | $— | $(2,643) | $2,643 | (100)% |

In February 2017, we sold the ANDAs that we acquired in March 2016 and recognized a gain of $2.6 million (see Note 8).

### Provision for income tax expense (benefit)

*(in thousands)*

|  | Three Months Ended March 31, 2018 | 2017 | Change Dollars% |  |
| --- | ---: | ---: | ---: | --- |
| Income tax expense (benefit) | $(1,784) | $611 | $(2,395) | NM |
| Effective tax rate | 20% | 41% |  |  |

The decrease in the effective tax rate for the three months ended March 31, 2018, was primarily due to the Tax Cuts and Jobs Act, or the Tax Act, which was enacted on December 22, 2017. The Act reduces the statutory U.S. federal corporate income tax rate from 35% to 21%.

### Liquidity and Capital Resources

### Cash Requirements and Sources

We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development‑stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand and improve our manufacturing facilities in the United States, China and France. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report on Form 10-Q. As of March 31, 2018, our foreign subsidiaries collectively held $12.4 million in cash and cash equivalents. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent company’s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.

We maintain a shelf registration statement on Form S-3 pursuant to which we may, from time to time, sell up to an aggregate of $250 million of our common stock, preferred stock, depositary shares, warrants, units, or debt securities. If we require or elect to seek additional capital through debt or equity financing in the future, we may not be able to raise capital on terms acceptable to us or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.

Working capital decreased $19.1 million to $101.5 million at March 31, 2018, compared to $120.6 million at December 31, 2017.

### Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the three months ended March 31, 2018:

*(in thousands)*

| Statement of Cash Flow Data: Net cash provided by (used in) | Three Months Ended March 31, 2018 |
| --- | ---: |
| Operating activities | $8,360 |
| Investing activities | (8,738) |
| Financing activities | (10,828) |
| Effect of exchange rate changes on cash | 159 |
| Net decrease in cash, cash equivalents, and restricted cash | $(11,047) |

#### Sources and Use of Cash

#### Operating Activities

Net cash provided by operating activities was $8.4 million for the three months ended March 31, 2018, which included net loss of $7.2 million. Non-cash items were comprised of $3.9 million of depreciation and amortization, and $4.7 million of share-based compensation expense. Operating assets and liabilities changed primarily due to the timing of sales and purchases activities in the normal course of business and the timing of the related cash receipts and disbursements.

#### Investing Activities

Net cash used in investing activities was $8.7 million for the three months ended March 31, 2018, primarily as a result of $12.3 million in purchases of property, machinery, and equipment, which included $3.3 million incurred in the United States, $5.4 million in France, and $3.6 million in China. The cash used was partially offset by the $4.4 million receipt of the remaining consideration of the sale of the various ANDAs in February 2017 (see Note 8 to the condensed consolidated financial statements for more information).

#### Financing Activities

Net cash used in financing activities was $10.8 million for the three months ended March 31, 2018, primarily as a result of $7.6 million used to purchase treasury stock and $1.8 million of net proceeds used to settle share-based compensation awards under our equity plans. Additionally, we made $1.4 million in principal payments on our long-term debt.

### Indebtedness

For more information regarding our outstanding indebtedness, see “Part I – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Debt”.

### Contractual Obligations

There have been no material changes outside the ordinary course of our business in the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, except that our outstanding debt obligations have changed as follows:

*(in thousands)*

|  | March 31, 2018 | December 31, 2017 | Change |
| --- | ---: | ---: | ---: |
| Short-term debt and current portion of long-term debt | $6,061 | $6,312 | $(251) |
| Long-term debt | 39,706 | 40,844 | (1,138) |
| Total debt | $45,767 | $47,156 | $(1,389) |

As of March 31, 2018, we had $43.0 million in unused borrowing capacity under revolving lines of credit with Cathay Bank and East West Bank.

### Critical Accounting Polices

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2017.

There were no material changes to our critical accounting policies during the three months ended March 31, 2018, other than the adoption of ASC 606, Revenue from Contracts with Customers, or ASC 606, using the modified retrospective transition method. The adoption of ASC 606 did not have a material impact on the Company’s revenue recognition or on the condensed consolidated financial statements and related disclosures. The results for the reporting period beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods.

### Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see “Part I – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Summary of Significant Accounting Policies”.

### Off-Balance Sheet Arrangements

We do not have any relationships or financial partnerships with unconsolidated entities, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

### Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The Food and Drug Administration, or FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration maintains oversight over our products that are considered controlled substances.

From April 19, 2018 to April 27, 2018, two contract laboratories that provide testing services for heparin sodium raw materials were inspected. The first inspection was for the laboratory providing testing services for our current heparin supplier. There was one Form 483 observation issued. The current heparin supplier plans to respond to the minor Form 483 within the required 15 working days and we expect the response to satisfy the requirements of the FDA and that no further actions will be necessary. The second inspection was for the laboratory providing testing services of heparin sodium for the pending submission for our facility in Nanjing China. These vendors are related to our filing for the heparin sodium. There were no Form 483 observations issued. The inspections covered compliance with Good Laboratory Practice regarding the analytical testing performed for heparin sodium release.

## Market risk

As filed, 4,423 characters.

*The following discussion provides forward-looking quantitative and qualitative information about our potential exposure to market risk. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).*

#### Investment Risk

We regularly review the carrying value of our investments and identify and recognize losses, for income statement purposes, when events and circumstances indicate that any declines in the fair values of such investments below our accounting basis are other than temporary. As of March 31, 2018, we did not have any such investments.

As of March 31, 2018, we had $5.2 million deposited in six banks located in China, $7.1 million deposited in one bank located in France, and $0.1 million deposited in one bank located in the United Kingdom. We also maintained $35.7 million in cash equivalents that include money market accounts as of March 31, 2018. The remaining amounts of our cash equivalent as of March 31, 2018, are in non-interest bearing accounts.

#### Interest Rate Risk

Our primary exposure to market risk is interest‑rate‑sensitive investments and credit facilities, which are affected by changes in the general level of U.S. interest rates. Due to the nature of our short-term investments, we believe that we are not subject to any material interest rate risk with respect to our short-term investments.

As of March 31, 2018, we had $45.8 million in long-term debt and capital leases outstanding. Of this amount, $14.6 million had variable interest rates which were not locked-in through fixed interest rate swap contracts. The debt with variable interest rate exposure had a weighted-average interest rate of 4.8% at March 31, 2018. An increase in the index underlying these rates of 1% (100 basis points) would increase our annual interest expense on the debt with variable interest rate exposure by approximately $0.1 million per year.

#### Foreign Currency Exchange Risk

Our finished pharmaceutical products are primarily sold in the U.S. domestic market, and have little exposure to foreign currency price fluctuations. However, as a result of our acquisition of the API manufacturing business in Éragny-sur-Epte, France, we are exposed to market risk related to changes in foreign currency exchange rates. Specifically, our insulin sales contracts are frequently denominated in Euros, which are subject to fluctuations relative to the U.S. Dollar, or USD.

Our Chinese subsidiary, ANP, maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD, using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in our statement of operations.

Our French subsidiary, AFP, maintains its books of record in Euros. Our U.K. subsidiary, IMS UK, maintains its books of record in Great Britain Pounds. These books are translated to USD at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income.

We are also exposed to the potential earnings effects from intercompany foreign currency assets and liabilities that arise from normal trade receivables and payables and other intercompany loans.

We do not undertake hedging transactions to cover our foreign currency exposure. As of March 31, 2018, a 10% unfavorable change in the exchange rate of the U.S. dollar strengthening against the foreign currencies to which we have exposure would result in approximately $1.8 million reduction of foreign currency gains, and approximately $5.2 million reduction in other comprehensive income.

As of March 31, 2018, our foreign subsidiaries had cash balances denominated in foreign currencies in the amount of $8.2 million.

## Controls and procedures

As filed, 3,211 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

### Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## Risk factors

As filed, 4,057 characters.

Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 14, 2018.

***Some of our products are marketed without FDA approval and may be subject to enforcement actions by the FDA.***

A number of our prescription products are marketed without FDA approval. These products, like many other prescription drugs on the market that FDA has not formally evaluated as being effective, contain active ingredients that were first marketed prior to the enactment of the FFDCA. The FDA has assessed these products in a program known as the “Prescription Drug Wrap-Up” and has stated that these drugs cannot be lawfully marketed unless they comply with certain “grandfather” exceptions to the definition of “new drug” in the FFDCA. These exceptions have been strictly construed by FDA and by the courts, and the FDA has stated that it is unlikely that any of the unapproved prescription drugs on the market, including certain of our drugs, qualify for the exceptions. At any time, the FDA may require that some or all of our unapproved prescription drugs be submitted for approval and may direct that we recall these products and/or cease marketing the products until they are approved. The FDA may also take enforcement actions based on our marketing of these unapproved products, including but not limited to the issuance of an untitled letter or a warning letter, and a judicial action seeking injunction, product seizure and civil or criminal penalties. The enforcement posture could change at any time and our ability to market such drugs could terminate with little or no notice. Moreover, if our competitors seek and obtain approval and market FDA-approved prescription products that compete against our unapproved prescription products, we would be subject to a higher likelihood that FDA may seek to take action against our unapproved products. Such competitors have brought and may bring claims against us alleging unfair competition or related claims.

As a result of our meetings with the FDA in 2009, we decided to discontinue all of our products that were subject to the Prescription Drug Wrap-Up program, with the exception of epinephrine in vial form. These products were all produced at our subsidiary, IMS. During the third quarter of 2010, the FDA requested that we reintroduce several of the withdrawn products to cope with a drug shortage, while we prepared and filed applications for approval of the products. Between August and October, 2010, we reintroduced atropine, calcium chloride, morphine, dextrose, epinephrine prefilled syringes, epinephrine injection, USP vial, and sodium bicarbonate injections.

In February 2017, the FDA requested that we discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which had been marketed under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. We discontinued selling this product in the second quarter of 2017. For the years ended December 31, 2017, 2016, and 2015, we recognized $17.8 million, $18.6 million, and $7.8 million in net revenues for the sale of this product, respectively.

In September 2017, the FDA granted approval of our ANDA for Sodium Bicarbonate injection.

For the years ended December 31, 2017, 2016, 2015, and the three months ended March 31, 2018 and 2017, we recorded net revenues of $35.4 million, $27.6 million, $27.8 million, $11.4 million, and $5.8 million, respectively, from the unapproved products currently on the market: atropine, calcium chloride, morphine, dextrose and epinephrine prefilled syringes. We have filed three ANDAs and one NDA with respect to the remaining unapproved products in order to mitigate all risk associated with the marketing of unapproved drug products. In the interim, we continue to operate within the FDA Compliance Policy Guide, CPG Sec. 440.100 Marketed New Drugs Without Approved NDAs and ANDAs.

Filed May 10, 2018.
Source: SEC EDGAR, the filing index for accession 0001297184-18-000029. Last ingested by Listed: Nov 6, 2026, 17:01 ET. No prices; not investment advice.
